ClinicalTrials.gg
Active, not recruitingNCT05780567Updated Apr 17, 2026

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

A Phase 3 interventional study of TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen and Placebo capsules, Letrozole, Anastrozole, Tamoxifen in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 3 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,946
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.

Planned enrollment
Largest of 15
1,946 · median 40
Started
2023
the only one that year
Phase 3
3 of 15
none open now
Primary completion
2026-12
later than 3 of 10 live
Registered
6th of 15
by date
Lead sponsor
8 of 15
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 15 studies testing culmerciclib in Breast Neoplasms, this one has the largest planned enrollment, is the only one that started in 2023, is one of 3 in phase 3, reaches primary completion later than 3 of the 10 other live ones, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About culmerciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing culmerciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 1946 female subjects will be randomized to either TQB3616 combined with endocrine group or TQB3616-matching placebo combined endocrine group. Randomization will follow a 2:1 ratio, 1297 subjects in experimental group and 649 in the the Placebo Comparator group.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study and signed the , with good compliance.
  • Age: 18-75 years old (upon signing the informed consent); Performance Status (PS) score: 0\~1;
  • Surgical treatment of radical mastectomy;
  • Pathological examination confirmed HR positive and negative invasive breast cancer;
  • The major organs are functioning well, meeting the following criteria:

    1. Blood biochemical tests should meet the following criteria (no corrective therapy has been used within 7 days prior to screening):

      1. (HB) ≥90 g/L;
      2. Neutrophil absolute value (NEUT) ≥ 1.5×109/L;
      3. count (PLT) ≥ 100 ×109/L;
    2. Blood biochemical tests should meet the following criteria (no corrective therapy has been used within 7 days prior to screening):

      1. Total (TBIL) ≤ 1.5 times the (ULN);
      2. Alanine transferase () and aspartate transferase (AST) ≤ 1.5×ULN;
      3. Serum creatinine (Cr) ≤ 1.5×ULN, or (Ccr) ≥ 60 ml/min;
    3. Blood clotting tests must meet the following criteria (no anticoagulant therapy):

      1. (PT) ≤ 1.5×ULN;
      2. Activated partial thromboplastin time (APTT) ≤ 1.5×ULN;
      3. International Normalized ratio (INR) ≤ 1.5×ULN.
    4. (LVEF) ≥50%.

Exclusion criteria

Exclusion Criteria:

  • Complicated diseases and medical history:

    1. Has had other malignant tumors within 5 years or currently has other malignant tumors;
    2. Have a variety of factors that affect oral medication (such as inability to swallow);
    3. Current history of serious lung disease such as interstitial pneumonia;
    4. Severe infections (≥CTCAE (common terminology criteria for adverse events) 2 grade) that were active or uncontrolled before the study treatment started (Except hair loss and );
  • Known allergy to aromatase inhibitors, tamoxifen, TQB3616/ placebo, or any ;
  • There was a history of vaccination within 28 days prior to randomization or live attenuated vaccine vaccination was planned during the study period;
  • Participated in clinical trials of other antitumor agents within 4 weeks prior to randomization;
  • The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of study participation or interfere with the study results, as well as subjects who are deemed unsuitable for study participation for other reasons by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,946 participants (estimated)

Study arms

  • Experimental
    TQB3616 capsules combined with endocrine

    The dose of TQB3616 capsules is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle. The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle. The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle. The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle.

    Drug: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen

  • Placebo comparator
    placebo combined with endocrine

    The dose of placebo is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle. The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle. The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle. The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle.

    Drug: Placebo capsules, Letrozole, Anastrozole, Tamoxifen

Interventions

  • DrugTQB3616 capsules, Letrozole, Anastrozole, Tamoxifen

    Drug pages: Culmerciclib · Letrozole · Anastrozole · Tamoxifen

    TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors. Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.

  • DrugPlacebo capsules, Letrozole, Anastrozole, Tamoxifen

    Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.

06

What researchers measure

Primary outcomes

  1. Invasive Disease-Free Survival (IDFS)

    The time from the date of randomization to the first occurrence of the following events, including ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, secondary primary malignancy outside the breast, and death from any cause.

    Time frame: Baseline up to 60 months

Secondary outcomes

  1. Overall survival (OS)

    The time from first administration to death of any cause.

    Time frame: Baseline up to 60 months

  2. Disease Relapse Free Survival (DRFS)

    The time from the date of randomization to the first occurrence of distant recurrence or death from any cause.

    Time frame: Baseline up to 60 months

  3. Incidence of adverse events

    Incidence of adverse events assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

  4. Severity of adverse events

    Severity of adverse events assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

  5. Incidence of abnormal laboratory test values

    Incidence of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

  6. Severity of abnormal laboratory test values

    Severity of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

  7. Incidence of serious adverse events

    Incidence of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

  8. Severity of serious adverse events

    Severity of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE).

    Time frame: Baseline up to 60 months

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 45 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Mar 22, 2023
StartActual
Mar 30, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05780567
Responsible party
Sponsor
First posted
Mar 22, 2023
Start date
Mar 30, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Culmerciclib · Letrozole · Anastrozole · Tamoxifen

Start the discussion